Monoclonal antibodies are being developed as therapeutics to complement drugs and
vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies …

Dengue is a significant global health problem. Even though a vaccine against dengue is
now available, which is a notable achievement, its long-term protective efficacy against each …

Antiviral antibodies constitute an important component of the host immune response against
viral infections and serve to neutralize and reduce infectivity of the virus. However, these …

Dengue is the most common viral infection spread by mosquitoes, prevalent in tropical
countries. The acute dengue virus (DENV) infection is a benign and primarily febrile illness …

Dengue virus (DENV) which infects about 390 million people per year in tropical and
subtropical areas manifests various disease symptoms, ranging from fever to life-threatening …

Dengue is the most important mosquito-borne viral pathogen globally, with approximately
100 million cases of acute dengue annually. Infection can result in severe, life-threatening …

Dengue virus (DENV) is the causative agent of dengue fever, dengue hemorrhagic fever,
and dengue shock syndrome and is endemic to tropical and subtropical regions of the world …

Dengue is considered the most important emerging, human arboviruses, with worldwide
distribution in the tropics. Unfortunately, there are no licensed dengue vaccines available or …

Introduction: Dengue is a prevalent disease in tropical and subtropical countries with an
estimated 400 million people infected annually. While significant advancement has been …

Several computational methods have been developed to identify neutralizing antibodies
(NAbs) covering four dengue virus serotypes (DENV-1 to DENV-4); however, limitations of …